Dataset Information

Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.

ABSTRACT: INTRODUCTION:The 19th Annual Meeting of the Society for Neuro-Oncology (SNO) took place in November of 2014. The focus of many abstracts, as well as the Education Day, was on recent advances in the study of central nervous system (CNS) metastases. TUMOR BIOLOGY:Key studies evaluating the factors in tumors and their microenvironment associated with the development and growth of brain metastases are reviewed. PROGNOSTICATION:Studies investigating the factors that independently influence survival in participants with brain metastases are presented. RESPONSE ASSESSMENT:The Response Assessment for Neuro-Oncology criteria for brain metastases (RANO-BM) and the Neurological Assessment in Neuro-Oncology (NANO) criteria, which were both presented, are recapped. RADIOTHERAPY:Studies are reviewed evaluating factors that influence survival outcomes in participants with brain metastases who were treated with radiotherapy. Studies investigating the potential risk of radiation necrosis with the combination of radiotherapy and immunotherapies are presented. SYSTEMIC THERAPIES:Brain metastases-focused subset analyses from the ASCEND-1 trial for ALK-translocated non-small cell lung cancer are presented. Preclinical and clinical work on solid tumor leptomeningeal carcinomatosis is also covered. SEQUELAE OF CENTRAL NERVOUS SYSTEM METASTASES AND THEIR TREATMENTS:An overview is provided of treatment- related toxicities as well as important concepts that may influence strategies to protect against these toxicities. CONCLUSIONS:Key concepts regarding tumor biology, prognostication, response assessment, therapeutic management, and sequelae of treatment for CNS metastases are summarized. Advances in our understanding of the basic and clinical science of CNS metastases have the potential to improve outcomes for patients.

SUBMITTER: Lukas RV

PROVIDER: S-EPMC5013812 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.

Lukas Rimas V RV Mehta Minesh P MP Lesniak Maciej S MS

Neuro-oncology practice 20150324 2

<h4>Introduction</h4>The 19th Annual Meeting of the Society for Neuro-Oncology (SNO) took place in November of 2014. The focus of many abstracts, as well as the Education Day, was on recent advances in the study of central nervous system (CNS) metastases.<h4>Tumor biology</h4>Key studies evaluating the factors in tumors and their microenvironment associated with the development and growth of brain metastases are reviewed.<h4>Prognostication</h4>Studies investigating the factors that independentl ...[more]

PMID: 27621837

Similar Datasets

Project description:We have reviewed the pivotal presentations rcelated to colorectal cancer (CRC) and other gastrointestinal malignancies from 2008 annual meeting of the American Society of Clinical Oncology (ASCO). We have discussed the scientific findings and the impact on practice guidelines and ongoing clinical trials. The report on KRAS status in patients with metastatic CRC receiving epidermal growth factor receptor (EGFR) targeted antibody treatment has led to a change in National Comprehensive Cancer Network guideline that recommends only patients with wild-type KRAS tumor should receive this treatment. The results of double biologics (bevacizumab and anti-EGFR antibody) plus chemotherapy as first-line treatment in patients with metastatic CRC has shown a worse outcome than bevacizumab-based regimen. Microsatellite Instability has again been confirmed to be an important predictor in patients with stage II colon cancer receiving adjuvant treatment. Adjuvant gemcitabine therapy for pancreatic cancer was investigated by the CONKO-001 study; this resulted in superior survival as compared with observation and can be regarded as an acceptable option, without the addition of radiotherapy. The addition of bevacizumab to gemcitabine and erlotinib was not supior to gemcitabine and erlotinib for advanced disease. Second-line therapy for advanced pancreatic cancer with 5-fluorouracil and oxaliplatin resulted in a survival benefit. Irinotecan plus cisplatin and paclitaxel plus cisplatin result in similar survival when combined with radiotherapy for esophageal cancer. The novel fluoropyrimidine S1 appears to be active in gastric cancer, as a single agent or as combination therapy. Adjuvant intraperitoneal mitomycin-C may decrease the incidence of peritoneal recurrence of gastric cancer. Sorafenib is an effective agent in Asian patients with hepatocellular carcinoma secondary to hepatitis B; its utility in child's B cirrhosis remains to be proven. Sunitinib is also an active agent in hepatocellular carcinoma, and may represent an alterative to sorafenib for advanced disease. These and other important presentations from the 2008 ASCO annual meeting are discussed in this article.

Dataset Information

Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.

Publications

Society for Neuro-Oncology 2014 annual meeting updates on central nervous system metastases.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets